ALKERMES PLC

Alkermes stock climbs 1.6% as its CNS pipeline fuels confidence; 7.3 B $ market cap shows steady gains, positioning the company for upcoming Phase‑III milestones.

Alkermes stock dips 1.43% as investors question its CNS breakthrough pipeline, trading at $44.18 amid market volatility and skepticism.

Alkermes shares jump 2.65%, trading near $44.37, with a $7.2B market cap and positive 200‑day trend, hinting at upside for biotech investors.